Accueil > Actualités > Communiqués


Mercredi 02 Mai 2018 à 07:30

Lyon, 2 May 2018 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, , will be delivering an oral presentation on its progress toward "a potential novel approach to treat Excessive Daytime Sleepiness (EDS): Targeting neurons and glial cells with THN102", at the European Conference on Narcolepsy to be held on 5 and 6 May in Montpellier.

Organised by Professor Yves Dauvilliers, this conference brings together European specialists in narcolepsy. They will discuss current knowledge in the areas of clinical research, neurophysiology, biomarkers, cognition and new therapeutic prospects. In this context, Dr Werner Rein, Chief Medical Officer of Theranexus, will be presenting the potential of Theranexus' new approach to treating EDS in narcoleptic patients with the drug candidate THN102, which targets neurons and glial cells.

I am delighted to present to the community of narcolepsy experts the innovative approach of our drug candidate THN102 and its proof of concept and application prospects in the area of excessive daytime sleepiness,” said Dr Werner Rein, Chief Medical Officer of Theranexus.

Theranexus has highlighted the key role of glial cells in the response to to Central Nervous System drugs (targeting only neurons), that are used in the treatment of certain neurological disorders. Research has shown, for the first time, that it is possible to increase the efficacy of these drugs by targeting glial cells. This increased efficacy allows for improved neuronal function and thus better management of the symptoms of neurological disorders. The patented drug candidate THN102, resulting from Theranexus' science thanks to its proprietary platform, is a combination of drugs, associating Modafinil (the reference treatment in narcolepsy) with Flecainide (a repositioned drug targeting glial cells). The THN102 candidate is expected to be significantly more effective than the reference treatment.

Presentation Information:
Speaker: Dr Werner Rein, Chief Medical Officer, Theranexus
Title: Targeting neurons and glia with THN102: a potential novel approach to treat excessive daytime sleepiness
Date and time: Saturday, 5 May at 5.45 pm
Location: Former Medical School in Montpellier


THN102 (modafinil/flecainide combination) for the treatment of wakefulness impairment in narcolepsy and Parkinson's disease is the most advanced drug candidate developed by Theranexus. Having demonstrated its superior performance compared with the standard treatment in healthy volunteers, it is currently in phase II in narcolepsy, an orphan disease affecting approximately 300,000 patients in Europe and the United States and representing a market valued at $2 billion. At the same time, THN102 will begin another phase II clinical trial on excessive daytime sleepiness in Parkinson's disease, the second-most common neurodegenerative disease. Excessive daytime sleepiness is a debilitating symptom, closely associated with impairment of attention and cognition in the disease. There is currently no authorised treatment for the management of this symptom, which affects 30% of patients with Parkinson's disease. These two phase II trials represent an opportunity for strong value creation by 2019 to be materialised through an industrial partnership.


This study entitled “Tolerance and efficacy of THN102 on sleepiness in narcoleptic patients” (NCT02821715) aims to demonstrate the superiority of THN102 over the reference treatment (modafinil) in narcoleptic patients with excessive residual daytime sleepiness despite treatment. It involves a minimum of 42 patients, is double-blind (neither the patient nor the doctor know which treatment is being assessed) and compares three treatments (modafinil 300 mg/day alone or in combination with two doses of flecainide, 3 and 27 mg/day) in cross-over over three periods: each patient receives each of the three treatments at random during three two-week periods. This study is coordinated by Professor Yves Dauvilliers, principal Investigator of the study, at the Montpellier University Hospital and is being conducted in parallel in five centres in France (Lille, Paris, Bordeaux, Garches and Montpellier). The main outcome of the phase II study is measured by the Epworth Sleepiness Scale (ESS), and the study will be successful if the THN102 drug candidate, with one or two doses, scores significantly lower than modafinil alone on this scale. Narcolepsy is a rare disorder with an estimated global prevalence of 56 cases per 100,000 in the United States and 47 cases per 100,000 in the European Union. 

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus-bourse.com



Thierry Lambert

Chief Financial Officer
ACTUS finance & communication
Caroline Lesage / Théo Martin

Investor Relations
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
Florence Portejoie

Media Relations
+ 33 (0)6 07 76 82 83

Partager sur Facebook
Article Précédent :
Article Suivant :

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 
Réactions à cet Article :

Maitretossa - Dimanche 02 Août 2020 à 16:51

Grand marabout vaudou,spécialiste de retour affectif

Grand marabout vaudou,spécialiste de retour affectif

Grand maître spirituel marabout sorcier vaudou, grande célébrité des travaux occulte vaudou,grand spécialiste des problèmes de couple, rituel de retour affectif rapide résultat en 7 jour :
Je détiens plusieurs connaissance dans le domaine de spirituel et je suis un grand guérisseurs basé sur la combinaison des plantes de la nature pour guérir plusieurs maladies . Je pratique aussi la magie blanche avec des rituels puissants pour faire les retours affectifs de l'être qu'on aime, je peux vous aider à reconquérir votre ex rapidement en 7 jours sans aucune conséquence, je pratique aussi des rituels à distance. je fais aussi les parfums de chance et les savons et pleins d'autre choses. Je suis vraiment sérieux à aider mon prochain en difficultés dans le but d'être reconnu plus dans plusieurs pays.
Pour une solution rapide et efficace à tous vos difficultés, vos besoins, vos demandes ,vos problèmes de vie, la déception,les problèmes de couple,problèmes d'amour, retour très rapide de votre ex, protéger votre couple ou votre famille, problème de la sorcellerie, problèmes avec la justice, problème familiale, devenir riche, chance aux jeux , trouver du Travail , occuper une place dans la société, guéri les maladies inconnues ,protection contre les mauvais sorts, contre poison, faites une consultation rapide claire et gratuite, trahison protection contre les esprits de la démence et de malchance, dés envoûtement d'amour, union rapide, les cas désespéré de retour d'affection, maître marabout spirituels PAPA TOSSA mettra tout son savoir faire pour vous donner une meilleur satisfaction.

NB: certains travaux sont gratuit ou la satisfaction après le payement si le cas nécessite beaucoup de dépense à faire et vous envoyé à distance .Je vous rassure beaucoup que plusieurs témoignent de mes bienfaits dans plusieurs pays. Et pour plus d'information , visitez mon
Site Web: https://www.marabout-vaudou-retour-affectif.com
N’attendez pas que votre problème s'aggrave, il y a des solutions pour chaque problème.N'attendez pas qu'il vous quitte, n'attendez pas qu'une autre personne lui jette un sort d'amour.Soit la fondation de votre relation ou de votre couple. N’hésitez pas à me contacter même s’il s'agit d’une simple question. Mon plaisir est d’aider ceux qui en ont vraiment besoin. Travail rapide et discret, résultat 100% garantit.
Je suis ouvert à toutes vos discutions et inquiétude si vous en aviez. Votre satisfaction fera mon plaisir.

Téléphone WhatsApp : 22 997 638 657
E-mail: contact.marabout.vaudou@gmail.com
SiteWeb: https://www.marabout-vaudou-retour-affectif.com/
Téléphone: 22 997 638 657


Maître Amangnon - Jeudi 25 Juin 2020 à 19:57

Grand Maître spirituel AMANGNON, votre marabout de référence

Le voyant AMANGNON est la personne qu’il vous faut pour améliorer votre quotidien et apporter la paix et la protection à votre foyer.
• La quête du grand amour
• La reconquête de votre ex ou de votre amour perdu
• L’amélioration de votre relation de couple
• Votre réussite professionnelle
• Blocage
• et autres
whatsApp: 22997788791

E-mail: contact.maitreamangnon@yahoo.com


NB: Je vous donne la preuve que mon travail marche avant tout engagement.


Herve.martinuzzi10@gmail.com - Mardi 18 Février 2020 à 09:45

Serious and fast loan service between individuals in France and reliable ranging from € 2,000 to € 800,000 (herve.martinuzzi10@gmail.com)

I'm Mr. Herve Martinuzzi. I am submitting a loan offer to you
individuals, to allow you to realize your dreams without worries. I write my text on this site, to help you, it is particular to obtain a serious financing, fast in transparency and traceability, my conditions are simple, not protocol. I indeed make loans between individuals to people who can meet my conditions. So if you need loan, credit, please answer me so that I can tell you about my offer. My interest rate is 3% and it spans the entire loan. My borrowing capacity is € 450,000. If you wish to have more information do not hesitate by… My e-mail address; herve.martinuzzi10@gmail.com


Les autres actualités

Retour vers 'Communiqués' »

Mots-clés : Oral   European   Neurological   Candidates   Neurons   Cells   Novel   Daytime   Targeting   Clinical   Cognition   Rein   Candidate   System   Drugs   Used   Neuronal   Flecainide   Most   Affecting   States   Symptom   Study   Being   Alone   Doses   Each   Psychotropic  
Sociétés citées dans cette news : FINANCIAL   Euronext  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?